Last reviewed · How we verify
ABBV-8736
At a glance
| Generic name | ABBV-8736 |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (PHASE2)
- A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers (PHASE1)
- A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-8736 CI brief — competitive landscape report
- ABBV-8736 updates RSS · CI watch RSS
- AbbVie portfolio CI